Abstract

We read with great interest the article by Suzuki et al. [1] regarding antegrade selective cerebral perfusion (SCP) with lower body circulatory arrest (LBCA) at moderate body core temperatures of 30–32°C. We agree with the authors that antegrade SCP, utilizing deep hypothermic circulatory arrest (21–27°C) to safeguard the protection of the visceral end-organs and the spinal cord, has become the most efficient neuroprotective strategy during transverse aortic arch repair over the past decades. However, as described by the authors, antegrade SCP is being increasingly utilized in combination with progressively increasing body core temperatures [1], a trend culminating in the advocation of moderate-to-mild temperatures (up to 35°C) and even normothermia [2]. Suzuki et al. report on their technique of total aortic arch repair in a contemporary series of 105 patients using a quadrifurcated Dacron graft. The authors proclaim that they routinely aim for deeper body core temperatures (25°C) to ensure lower body-organ protection when LBCA is expected to exceed a duration of 30 min. However, the authors also state that in ‘almost all cases... the core temperature was still 30–32°C’ with a mean LBCA time of 58 ± 22 min in the reported series [1]. This progressive approach may bear potential risks for the non-perfused organs in case of prolonged operation times—apparently not only in case of unexpected technical problems (as documented by an average of 58 min of LBCA) [3, 4]. The authors also admit that they are not familiar with the safe limits of spinal cord ischaemic tolerance during distal circulatory arrest at mild hypothermia. In fact, the ischaemic tolerance of the spinal cord and the visceral organs has not yet been clearly defined, and is therefore not well recognized in clinical practice. A consensus paper of the EACTS Vascular Domain is currently underway to address this issue. However, with regard to recent experimental data, the safe ischaemic interval for the spinal cord—utilizing the currently available state—of—the—art adjuncts for intraoperative neuroprotection—may be estimated as follows [2, 5]:

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.